BioCentury

8:00 AM GMT, Feb 4, 2008
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.
Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 2/1 cls
Achillion (NASDAQ:ACHN) JMP Securities Liisa Bayko New Market perform 29% $5.38
Bayko expects 24-week data soon from a Phase II trial of elvucitabine to treat HIV infection, which she said will shed light on the "partnerability" of the nucleoside reverse transcriptase inhibitor (NRTI). Bayko also expects an IND submission for ACH-1095 to treat HCV infection in 2H08. The non-structural protein 4A (NS4A) antagonist is partnered with Gilead (NASDAQ:GILD).
Acorda (NASDAQ:ACOR) Banc of America Securities William Ho Price target Buy 23% $26.86
Fortis Patrick Moriarty Price target Buy
Lazard Joel Sendek Price target Buy
Ho raised his target to $33 from $26 after Acorda announced that the electrocardiographic QT interval with Fampridine-SR treatment

Read the full 1265 word article

This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.